Launch of public consultation on ACT EU multi-stakeholder platform until 3rd March 2023
Answer the survey before 3rd of March 2023 at midnight CET.
The European Medicines Agency has launched a public consultation concerning the development of a multi-stakeholder platform to promote collaboration for improving clinical trials in the EU as foreseen by Accelerating Clinical Trials in the EU (ACT EU) priority action 3.
This platform will enable regular dialogue between all EU stakeholders on clinical trials, and facilitate the evolution of the clinical trials environment by helping to identify key advances in clinical trial methodologies, technology and science. The platform will serve as a neutral space for the discussion of challenges and the development of practical solutions to enable and drive change. It is envisaged that there will be several phases of development before reaching its final design.
A concept paper outlining the proposal for the creation of the platform has been published together with the public consultation. The objective of which is to gauge interest in the platform, get feedback on priority topics for discussion, and provide comments on the proposal. The multi-stakeholder platform will have its kick-off meeting in Q2 2023.
The public consultation can be accessed at the following survey: EUSurvey - Survey (europa.eu) and will remain open until 03 March 2023 at midnight CET.
Those interested can find more information on the web page Accelerating Clinical Trials in the EU (ACT EU).
For any questions, stakeholders can contact ACTEU(ELIMINAR)@ema.europa.eu.